GSK completes demerger of Haleon

GSK

GSK plc (LON:GSK) has completed the demerger of the Consumer Healthcare business from the GSK Group to form the Haleon Group. The shares of Haleon plc (ticker “LSE: HLN”) will be admitted at 8.00 a.m. today to the Premium Listing segment of the Official List and to trading on the Main Market of the London Stock Exchange.

It is expected that American Depositary Shares representing shares of Haleon plc (ticker: “NYSE: HLN”) will commence “regular-way” trading on the New York Stock Exchange at market open on Friday 22 July 2022. In addition, we expect that Haleon ADSs will begin trading on a “when-issued” basis on the NYSE from market open today up to and including Thursday 21 July 2022. Each Haleon ADS represents two Haleon ordinary shares.

GSK Share Consolidation

At the GSK General Meeting on 6 July 2022, alongside the demerger, GSK shareholders also approved the consolidation of GSK shares (the “GSK Share Consolidation”). The GSK Share Consolidation is expected to take place after the market closes today. It is expected that admission and dealings in the new GSK shares on the LSE will commence at 8.00 a.m. on Tuesday 19 July 2022. GSK will provide an update following the completion of the GSK Share Consolidation at around 7.00 a.m. on Tuesday 19 July 2022.

The ratio for the GSK Share Consolidation cannot be fixed at this time as it will depend on fluctuations in the volume and price of the GSK shares in the period between 8.00 a.m. and 4.30 p.m. today.

As at the time of this announcement, GSK’s issued share capital consists of 5,389,096,045 ordinary shares of 25 pence each (including 304,905,950 ordinary shares held in treasury). Therefore, the total number of voting rights in the Company is 5,084,190,095. If the total number of GSK shares in issue prior to the record time at 8.00 p.m. today is not exactly divisible by the denominator in the consolidation ratio, then shortly before the GSK Share Consolidation, GSK will issue up to 49 ordinary shares to ensure that following the GSK Share Consolidation there are no fractional ordinary shares outstanding.

Further information on and key dates in relation to the proposed demerger of Haleon and the GSK Share Consolidation is set out at the end of this announcement and can also be found in the Circular to Shareholders published on 1 June 2022. The Circular is available on GSK’s website at www.gsk.com/demerger.

Expected Timetable of Principal Events

The times and dates set out in the timetable below and throughout this announcement are indicative only and based on GSK’s current expectations and may be subject to change without further notice.

EventTime and date(1)
Commencement of dealings in Existing GSK Shares (ex entitlement to Haleon Shares) on the LSE8 a.m. on Monday 18 July 2022
Admission and commencement of dealings in Haleon Shares on the LSE8 a.m. on Monday 18 July 2022
CREST accounts credited in respect of Haleon Shares in uncertificated formAs soon as practicable after 8 a.m. on Monday 18 July 2022
GSK Share Consolidation record time–8 p.m. on Monday 18 July 2022
GSK Share Consolidation becomes effectiveAfter 8 p.m. on Monday 18 July 2022
GSK Admission and commencement of dealings in New GSK Shares on the LSE8 a.m. on Tuesday 19 July 2022
CREST accounts credited in respect of New GSK Shares in uncertificated formAs soon as practicable after 8 a.m. on Tuesday 19 July 2022
Commencement of trading in Haleon ADSs on a “when-issued” basis on the NYSE9.30 a.m. New York City time on Monday 18 July 2022
Commencement of “regular-way” trading in Haleon ADSs on the NYSE9.30 a.m. New York City time on Friday 22 July 2022
Admission and commencement of dealings in new GSK ADSs on the NYSE9.30 a.m. New York City time on Friday 22 July 2022
Opening of the GSK ADS issuance and cancellation books (2)8 a.m. New York City time on Monday 25 July 2022
Latest date for despatch of:-     definitive share certificates (where applicable) for New GSK Shares in certificated form to Qualifying Shareholders on the GSK Share Register

By Monday 1 August 2022
–     CSN statements for GSK CSN(3)By Monday 1 August 2022
–     definitive share certificates (where applicable) for Haleon Shares in certificated form to Qualifying Shareholders on the GSK Share Register(4)By Thursday 4 August 2022
–     opening statements for Haleon CSN(3) (4)By Thursday 4 August 2022
Posting of payment advice, CREST accounts credited or payment by electronic payment in respect of fractional entitlements arising from the GSK Share ConsolidationWeek commencing Monday 1 August 2022

Notes

(1)  Unless otherwise indicated, all references to time in this timetable are to UK time.

(2)  The Depositary will suspend the issuance and cancellation of GSK ADSs from Thursday 14 July 2022 until Monday 25 July 2022. This means that during this time, you will not be able to convert your GSK ADSs into GSK Shares, surrender your GSK ADSs and receive underlying GSK Shares, or deposit your GSK Shares and receive GSK ADSs. However, the closing of the issuance and cancellation books does not impact trading, and you may continue to trade your GSK ADSs during this period.

(3)  For CSN Shareholders who have a Shareview Portfolio account, and have not elected for paper statements to be issued to them, the CSN statements will only be made available electronically via their account.

(4)  Subject to the timing of the Haleon Capital Reduction.

Share on:

Latest Company News

GCP Infrastructure reports 8.0% portfolio yield and stronger balance sheet

GCP Infrastructure Investments has reported a 98.60 pence net asset value, portfolio valuation of £810.4 million and further debt and asset sale updates.

Plus500 expands US trading offering with new Single Stock Futures

Plus500 has launched Single Stock Futures in the US, broadening customer access to CME Group-listed contracts and leading US stocks.

Clarkson reports record first-half profit and raises interim dividend

Clarkson Plc reported record first-half profit, lifted interim dividend and said full-year performance is expected to be materially ahead of market expectations.

Ilika plc reaches a commercial turning point as new markets emerge for Stereax and Goliath (video)

Dr Tom McColm of Morphose Capital Partners explains why the company may be approaching an important commercial inflection point.

Alien Metals notes start of 8,300m West Pilbara drill program

Alien Metals notes GreenTech has started an 8,300 metre drill programme at Whundo and Munni Munni in Western Australia.

HICL Infrastructure reports resilient performance and advances strategic evolution

HICL Infrastructure Plc reports portfolio performance in line with expectations, an additional Cross London Trains stake, and reaffirmed dividend guidance.

    Search